TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9469531
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1 mg/ml morphine and 3 mg/ml ketorolac
Study: 8203838
Drug: ofloxacin plus
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ofloxacin plus roxithromycin (150 mg twice daily)
Study: 22404250
Drug: Two-step technique
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step technique (first treating only reticular veins with a single injection at the base of each cluster of telangiectasias, then successively injecting all remaining telangiectasias a few minutes later)
Study: 3501750
Drug: Ofloxacin 100mg
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin 100mg twice daily for 3 days
Study: 8749149
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg daily
Study: 17496674
Drug: Neuromonics Tinnitus
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromonics Tinnitus Treatment (first variation)
Study: 17496674
Drug: Neuromonics Tinnitus
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromonics Tinnitus Treatment (second variation)
Study: 31308344
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with HDM 300 IR tablets for 52 weeks
Study: 3535552
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose piperacillin
Study: 18613992
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment group (lifestyle changes, red yeast rice, and fish oil)
Study: 10713867
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Remifentanil and Propofol (group RP)
Study: 2379228
Drug: Cloxacillin 500
Normalized name: cloxacillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxacillin 500 mg orally thrice daily for seven days
Study: 3880879
Drug: Dexamethasone therapy
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone therapy
Study: 17531887
Drug: Low-dose NaFeEDTA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose NaFeEDTA (28 mg/kg)
Study: 17531887
Drug: Electrolytic iron
Normalized name: electrolytic iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrolytic iron (56 mg/kg)
Study: 10677394
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of high dose (250 mg/250 mg) of lactulose/rhamnose
Study: 30958879
Drug: Activity impairment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity impairment improvement with acute-phase treatment in STAR∗D (F = 7.27; df = 2,2625; P <. 001)
Study: 2675434
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nitrazepam
Study: 19542901
Drug: Alglucosidase alpha
Normalized name: Alglucosidase alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alglucosidase alpha 20 mg/kg biweekly
Study: 15023154
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 1000 mg three times a day
Study: 8281693
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol (EE), 35 micrograms, intravenous administration
Study: 19185645
Drug: Anacetrapib 10
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib 10 mg once daily for 8 weeks
Study: 19185645
Drug: Anacetrapib 40
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib 40 mg once daily for 8 weeks
Study: 6476586
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg atropine sulfate
Study: 15230341
Drug: Cefaclor extended
Normalized name: Cefaclor Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor extended release 500‐mg tablet after low‐fat vegetarian diet
Study: 15230341
Drug: Cefaclor extended
Normalized name: Cefaclor Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor extended release 500‐mg tablet after high‐fat non-vegetarian diet
Study: 3291657
Drug: Radiation followed
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation followed by 6 cycles of MOPP chemotherapy (159 patients)
Study: 22535269
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (perindopril +/‐ indapamide)
Study: 3773181
Drug: Drug information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug information sheet
Study: 10206320
Drug: Azimilide 35
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 35 mg day(-1)
Study: 22548394
Drug: Flumetasone ointment
Normalized name: flumetasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumetasone ointment plus 308-nm excimer laser therapy
Study: 22017520
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg/day
Study: 12040291
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration at 7:00 am
Study: 12040291
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration at 7:00 pm
Study: 27143319
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (control group)
Study: 27143319
Drug: Renal denervation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal denervation (RDN) plus optimal medical therapy
Study: 3877303
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion for maintenance of anaesthesia
Study: 2887153
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% ALO 2145
Study: 20731494
Drug: Infant Health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant Health and Development Program treatment group
Study: 11426360
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone
Study: 26403206
Drug: Preoperative ultrasound-guided
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative ultrasound-guided femoral nerve block (FNB) with 20 mL of 0.5% bupivacaine
Study: 18303408
Drug: FPDNA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPDNA levels above cutoff after chemotherapy
Study: 16842390
Drug: Fexofenadine 120
Normalized name: fexofenadine hydrochloride 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 120 mg
Study: 31331968
Drug: Dalfampridine 10
Normalized name: dalfampridine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine 10 mg twice daily for 12 weeks
Study: 23018816
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment
Study: 12747273
Drug: Diclofenac hydroxyethylpyrrolidine
Normalized name: diclofenac hydroxyethylpyrrolidine 1.292 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac hydroxyethylpyrrolidine (DHEP) patch
Study: 11673813
Drug: Remune monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remune monotherapy (administered every 12 weeks)
Study: 12504657
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 10 mg/m2 on day 1 and continuous infusion of 5-fluorouracil (5-FU) 200 mg/m2
Study: 7786531
Drug: Propafenone 300
Normalized name: propafenone 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 300 mg twice daily
Study: 15570084
Drug: Tipifarnib 600
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib 600 mg bid
Study: 15963197
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg once daily for 12 weeks
Study: 29203355
Drug: drisapersen 6
Normalized name: drisapersen
DrugBank: Drisapersen (DB13688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drisapersen 6 mg/kg/week
Study: 17286569
Drug: ATP injection
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP injection during intravenous isoproterenol infusion (ISP-infusion) after successful extensive encircling pulmonary vein isolation (EEPVI)
Study: 17286569
Drug: ATP injection
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP injection
Study: 8605125
Drug: Amniotomy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amniotomy followed by oxytocin infusion after 1 h (group A, n = 98)
Study: 7094971
Drug: Clomipramine (C1)
Normalized name: C1-INH
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine (C1) at 75 mg per day
Study: 28394665
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ablative ultrapulse CO2 followed by fixed-dose QS Nd:YAG laser (1064 nm)
Study: 31175814
Drug: Active Music
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Music Therapy (MT)
Study: 14573318
Drug: Antidepressant-free patients
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant-free patients
Study: 26529159
Drug: efavirenz-based therapy
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz-based therapy
Study: 26529159
Drug: ritonavir-boosted lopinavir-based
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: ritonavir-boosted lopinavir-based therapy
Study: 10599373
Drug: Betamethasone propionate
Normalized name: calcipotriene 0.005 % / betamethasone propionate 0.064 % Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone propionate cream alone
Study: 8698947
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy
Study: 2018160
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy with buspirone
Study: 2018160
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy with placebo
Study: 14755152
Drug: Herbal preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal preparation STW 5‐II
Study: 8659218
Drug: Postoperative low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative low molecular weight heparin (tinzaparin)
Study: 17067720
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (150 microg/mL)
Study: 12566476
Drug: CHO Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO Group (Carbohydrate Group) consuming a diet with a CHO/protein ratio of 3.5 (68 g protein/d)
Study: 21180275
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine Ringer's solution)
Study: 9398894
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg + Metronidazole 400 mg + Clarithromycin 250 mg (OMC250)
Study: 16937305
Drug: Concurrent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin (CDDP) at 30 mg/m(2) for weekly schedule
Study: 21968267
Drug: Radioactive iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radioactive iodine therapy
Study: 12782435
Drug: Diamorphine gel
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine gel
Study: 28006831
Drug: Desmopressin tablets
Normalized name: desmopressin Sublingual Tablet
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin tablets
Study: 19825326
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (15 mg of sibutramine)
Study: 31039806
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of donepezil for 4 weeks before escalating to 23 mg (group 1)
Study: 31039806
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg and 23 mg on alternate days for 4 weeks prior to escalation (group 2)
Study: 30897305
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg and caffeine 100 mg (FDC)
Study: 30897305
Drug: Ibuprofen lysinate
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen lysinate
Study: 12957441
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg daily for two months
Study: 3323074
Drug: Ceftazidime single
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime single preoperative 2 g intramuscular dose (group A)
Study: 10975587
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg daily
Study: 24176784
Drug: Whole-systems Ayurveda
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-systems Ayurveda and Yoga Therapy
Study: 21484739
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injections (14 patients)
Study: 16180951
Drug: Problem-oriented willed-movement
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-oriented willed-movement (POWM) therapy
Study: 12844392
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid added to ice creams
Study: 3965236
Drug: Intravenous pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentoxifylline (200 mg)
Study: 3965236
Drug: Oral pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentoxifylline (400 mg)
Study: 3965236
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous dosing
Study: 19495958
Drug: docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 100 mg/m(2) q3w
Study: 17684468
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate and biotin combination
Study: 11967494
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 0.01% recombinant human platelet-derived growth factor gel
Study: 25545757
Drug: Oral glutamic
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral glutamic acid
Study: 15149872
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) and Vitamin C and E (VCE)
Study: 15569362
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg b.i.d. plus mosapride 5 mg t.d.s. (group B)
Study: 10659896
Drug: Oxytocin (intravenous)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (intravenous)
Study: 29720374
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (CSI; n=66)
Study: 25060803
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (clobetasol propionate) before and just after PDT
Study: 20160654
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 0.2 mg/kg per day
Study: 3527626
Drug: Insulin responses
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin responses
Study: 17445751
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg twice a day
Study: 31853550
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone replacement
Study: 2497545
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ASA
Study: 9718051
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate (hormone group)
Study: 25308350
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin administration
Study: 7473964
Drug: Injection into
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection into the antecubital fossa
Study: 7473964
Drug: Injection into
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection into the dorsum of the hand
Study: 8251277
Drug: PCA only
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA only (bolus dose 20 micrograms kg‐1 with a lockout interval of 5 min)
Study: 12019107
Drug: Zidovudine (AZT)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (AZT) at 250 to 300 mg twice daily, 3TC at 150 mg twice daily, and indinavir at 800 mg every 8 h
Study: 17161655
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vimentin methylation plus DNA integrity assay (DIA).
Study: 22127844
Drug: Bosentan therapy
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan therapy
Study: 20578829
Drug: Early CVC
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early CVC removal (within 24 or 48 hours after treatment initiation)
Study: 9798806
Drug: Otilonium bromide
Normalized name: otilonium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilonium bromide 40 mg t.d.s.
Study: 15842150
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) for chronic disease treatment
Study: 12017351
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 10 mg as a 5-minute i.v. infusion
Study: 371056
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg salbutamol solution
Study: 6354826
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (375 and 750 mg/day)
Study: 15776131
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium 10 mg
Study: 2971565
Drug: Inhaled ipratropium
Normalized name: ipratropium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ipratropium bromide
Study: 21937811
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg oral administration alone, twice daily for 4 weeks
Study: 9002327
Drug: Reduced-osmolarity maltodextrin-based
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-osmolarity maltodextrin-based ORS (MD 50 g/l, osmolarity 227 mmol/l)
Study: 27526979
Drug: Rifampicin 750
Normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 750 mg orally
Study: 1684273
Drug: Ebastine 10
Normalized name: ebastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10 mg once daily for seven days
Study: 7067924
Drug: Repeat action
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat action tablet (60 mg d-pseudoephedrine sulfate in the coat and 60 mg d-pseudoephedrine sulfate in the core)